Cancer Research Technology
Log in Register
Menu
Search
Monoclonal Antibodies

Anti-PAT4 [PAT-4/9/H10]

Invented by Helen Turley from University of Oxford , Prof Deborah Goberdhan from University of Oxford
Invented at University of Oxford
  • Datasheet
  • Inventor Info
Print

Info

Image thumbnail for Anti-PAT4 [PAT-4/9/H10]
Image thumbnail for Anti-PAT4 [PAT-4/9/H10]
Image thumbnail for Anti-PAT4 [PAT-4/9/H10]
Add an image
Formalin-fixed, paraffin-embedded 786-O cells incubated with PAT4 monoclonal antibody (Pat4/9/H10) and visualised with 3,3'-diaminobenzidine (DAB). There is an obvious perinuclear region of staining visible in most cells treated with the scrambled control siRNA (a). This staining is absent when the PAT4 transcript is knocked down using an siRNA against PAT4 (b). (from Fan et al. 2015. Oncogene. :. PMID: 26434594.)
Western blot analysis of serial dilutions of cell lysates (15, 7.5 and 3.8 μg of protein) produced from pools of 786-O cells carrying an IPTG-inducible shPAT4 (43587; shPAT4) probed with PAT4 monoclonal antibody Pat/9/H10. This reveals a set of bands from 60–75 kDa that is strongly reduced by IPTG-induced PAT4 knockdown (+IPTG), suggesting that they are PAT4-specific. Western blots were also probed with an anti-tubulin antibody as a loading control. (from Fan et al. 2015. Oncogene. :. PMID: 26434594.)
Western blot of cell lysates from 786-O cells and from a GFP-PAT4-overexpressing HEK-293 cell line treated with PNGase F before electrophoresis to remove glycosyl groups. This resolves the crossreacting molecules seen in untreated cell lysates into more specific bands migrating at ~30 and 50 kDa, respectively, smaller than the predicted molecular weights of 55 kDa (PAT4) and 85 kDa (GFP-PAT4), a phenomenon also reported for other transmembrane proteins. (from Fan et al. 2015. Oncogene. :. PMID: 26434594.)
Add an image
Image thumbnail for Anti-PAT4 [PAT-4/9/H10] Image thumbnail for Anti-PAT4 [PAT-4/9/H10] Image thumbnail for Anti-PAT4 [PAT-4/9/H10]
Catalogue Number 152743
Applications IHC WB
Antigen/Gene or Protein Targets PAT4 (SLC36A4)
Reactivity Human
Relevance The Anti-PAT4 [PAT-4/9/H10] antibody is a highly specific mouse monoclonal antibody against PAT4. Members of the proton-assisted amino-acid transporter (PAT) or solute-linked carrier 36 (SLC36) family have been identified as positive regulators of growth and mTORC1 signalling in flies.These effects were shown to be conserved by characterisation of the two ubiquitously transcribed human PATs, PAT1 (SLC36A1) and PAT4 (SLC36A4). PAT4 is upregulated in aggressive forms of colorectal cancer and a possible biomarker.
Host Mouse
Immunogen Antigenic amino acid sequence within the N-terminus of PAT4 (REELDMDVMRPLINE-C).
Positive Control 786-O human renal cancer cells
Subclass IgG2a kappa
Molecular Weight (kDa) ~60
Myeloma Used P3/NS1/1-Ag4.1
Recommended Growing Conditions RPMI 10% FCS plus HAT essential
Notes A monoclonal antibody against PAT4 was created by immunising mice with a keyhole limpet haemocyanin-conjugated, cysteine-coupled peptide (Severn Biotech Ltd., Kidderminster, UK) based on an antigenic amino-acid sequence within the N terminus of PAT4 (REELDMDVMRPLINE-C).
Research Area Cell Signaling & Signal Transduction, Metabolism

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Fan et al. 2015. Oncogene. :. PMID: 26434594.

View  

PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer.

Europe PMC ID: 26434594

View  

Add a reference

References: 2 entries

Fan et al. 2015. Oncogene. :. PMID: 26434594.

View  

PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer.

View  

Add a reference

Inventor Information